FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, particularly to the compositions of biocompatible microparticles of alginic acid for regulated release of the active ingredients in intravenous introduction, to a method for preparing and using it. The composition contains microparticles of alginic acid of 5 mcm or less with negative Z-potential; the active ingredient represents blood coagulation factor.
EFFECT: group of inventions provides a combination of size adequate for prolongation of blood half-life or survival of the active ingredient, with lower hepatic absorption and fast cell clearance in intravenous introduction.
23 cl, 5 ex, 8 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS OF PEGYLATED LIPOSOMES AND COAGULATION FACTORS | 2015 |
|
RU2737291C2 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| COMBINED APPLICATION OF FACTOR VII POLYPEPTIDES AND FACTOR VIII POLYPEPTIDES | 2002 |
|
RU2311923C2 |
| METHOD OF PRODUCING POWDER CONTAINING PROTEIN WHICH IS HUMAN BLOOD COAGULATION FACTOR AND LACTIC ACID-BASED POLYMER | 2016 |
|
RU2702740C2 |
| CHEMERIC IMPROVED RECOMBINANT FACTOR VIII | 2015 |
|
RU2647769C2 |
| METHOD OF SEPARATING VIII FACTOR FROM BLOOD PRODUCTS | 2017 |
|
RU2734783C2 |
| MODIFIED VON WILLEBRAND FACTOR WITH PROLONGED HALF-CYCLE IN VIVO, USING IT AND METHODS FOR PREPARING | 2009 |
|
RU2528855C2 |
| RECOMBINANT DNA MOLECULE ENCODING OF MODIFIED SWINE FACTOR VIII (POL1212), EXPRESSION VECTORS, MODIFIED SWINE FACTOR VIII, THERAPEUTIC COMPOSITION, METHODS FOR PRODUCTION OF MODIFIED SWINE FACTOR VIII PROTEIN (VARIANTS) AND CELL LINES (VARIANTS) | 2001 |
|
RU2285724C2 |
| FVIII MODIFICATION TREND SITE | 2005 |
|
RU2423380C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION | 2019 |
|
RU2799048C2 |
